

1 ***APOE4* and Infectious Diseases Jointly Contribute to Brain Glucose Hypometabolism, a Biomarker of**
2 **Alzheimer's Pathology: New findings from the ADNI**

3 Aravind Lathika Rajendrakumar^{1§§}, Konstantin G. Arbeev¹, Olivia Bagley¹, Anatoliy I. Yashin¹, Svetlana
4 Ukraintseva^{1§§}; for the Alzheimer's Disease Neuroimaging Initiative[§]

5

6 **Abstract**

7 **Introduction**

8 We investigated the interplay between infections and *APOE4* on brain glucose hypometabolism, an early
9 preclinical feature of Alzheimer's Disease (AD) pathology.

10 **Methods**

11 Multivariate linear regression analysis was performed on 1,509 participants of the Alzheimer's Disease
12 Neuroimaging Initiative (ADNI). The outcomes were the rank-normalized hypometabolic convergence
13 index (HCI) and statistical regions of interest (SROI) for AD and mild cognitive impairment (MCI). Further,
14 the HCI and its change in the presence and absence of *APOE4* were evaluated.

15 **Results**

16 Infections were associated with greater hypometabolism [0.15, 95% CI: 0.03, 0.27, p=0.01], with a more
17 pronounced effect among *APOE4* carriers, indicating an interaction effect. A higher HCI (0.44, p=0.01) was
18 observed in *APOE4* carriers with multiple infections, compared to (0.11, p=0.08) for those with a single
19 infection, revealing a dose-response relationship. The corresponding estimates for the association of
20 infections with SROI AD and SROI MCI were -0.01 (p=0.02) and -0.01 (p=0.04) respectively.

21 **Conclusion**

22 Our findings suggest that infections and *APOE4* jointly contribute to brain glucose hypometabolism and
23 AD pathology, supporting a “multi-hit” mechanism in AD development.

24

25 **Keywords**

26 Alzheimer’s Disease, Infections, Hypometabolic Convergence Index, Statistical Regions of Interest, *APOE4*,
27 Brain Hypometabolism

28 **1 Introduction**

29 Alzheimer’s disease (AD) is a slowly developing neurodegenerative disorder that is clinically manifested
30 as dementia.¹ The current figure for the AD burden in older adults in the United States is 6.7 million, and
31 it is poised to rise to 13.8 million by 2060.² The preclinical stage of AD can last many years without obvious
32 signs of dementia.³ It is crucial to better understand this preclinical stage in order to develop successful
33 AD prevention.⁴ Common preclinical features of AD include toxic protein depositions, neuronal apoptosis
34 and reduction in hippocampal volume (brain shrinkage), and brain glucose hypometabolism.^{5,6} The brain
35 glucose hypometabolism is observed long before the occurrence of overt symptoms in AD and is partly
36 due to mitochondrial dysfunction.⁷ Measuring glucose utilization in the brain using positron emission
37 tomography (PET) and 18F-fluorodeoxyglucose (FDG) allows for convenient examination of
38 hypometabolic patterns in the brain.⁸ Brain scans based on FDG PET can effectively detect around 90% of
39 AD-specific metabolic patterns, such as those in the parieto-temporal, frontal, and posterior cingulate
40 regions.⁹

41 A large genetic component drives AD (60-80%), and the entire spectrum of the disease can develop over
42 15-25 years.¹⁰ Genetic variations in the *APOE* gene could single-handedly account for a large part of the
43 risk related to AD in old age.¹¹ On the other hand, addressing modifiable risk factors could reduce or delay
44 up to 40% of dementia risk.¹² Therefore, by focusing on the modifiable risk factors, a substantial part of

45 the AD burden could be alleviated at the population level.¹³ Prevention of certain infections can reduce
46 the risk of chronic diseases, including neurological deficits.^{14–16} Accumulating evidence suggests that
47 infections could be a significant risk factor for AD that may also facilitate the development of AD pathology
48 at the preclinical stage, though the exact mechanism is unclear and might involve a direct detrimental
49 impact of infection-related factors as well as indirect effects of compromised immunity.^{17–20}

50 The connection between infections and AD and related pathology may also be influenced by genetic
51 factors.^{18,21,22} There are also indications that infections can contribute to brain hypometabolism, one of
52 the earliest features of AD pathology; however, research on this topic is scarce.²³ Here we explore how
53 infectious diseases may influence brain glucose metabolism in presence and absence of *APOE4*, the
54 strongest genetic risk factor for AD, in participants of the Alzheimer’s Disease Neuroimaging Initiative
55 (ADNI).

56

57 **2 Data and Methods**

58 **2.1 Study Population**

59 ADNI is a multi-center observational study that began in 2004 under the supervision of Michael W.
60 Weiner. The study recruited individuals within the 55-90 years age range, and enrollment in this cohort
61 occurs in different phases, with previous participants continuing to be in the study and new participants
62 being recruited. To compare and gain knowledge about dementia, this database maintains and updates
63 demographic, phenotypic, biomarker, and genetic data gathered from participants with normal cognition,
64 AD, and other forms of cognitive impairment. The availability of such a wide variety of biomarkers
65 provides sufficient information to learn about the evolution and pathology driving AD.²⁴

66 More details regarding the study design and objectives can be accessed here
67 (<https://adni.loni.usc.edu/study-design/>). Broadly, ADNI seeks to integrate information from biomarkers,

68 cognitive measures, and brain scans to improve AD diagnosis and treatment.²⁵ Brain scans were primarily
69 collected to learn about the structural and metabolic functions of the brain, serving as a standard for
70 differentiating the pathological changes seen in AD from those in normal aging.²⁶

71 **2.2 Predictors: Infections and *APOE4***

72 Prior infections were determined by combining the information from medical history, baseline symptoms,
73 initial health assessment, and adverse effects datasets. The details of the selected subset of infections
74 included in the final dataset are illustrated in Supplementary Figure 1. Medical history information was
75 collected during screening visit using a questionnaire. Non-harmonious disease names were uniformly
76 labeled for analytical purposes. Duplicated participant information having the same infection and
77 diagnosis date, as well as any infections lacking a diagnosis date, were subsequently excluded. Covariates
78 such as age, sex, education, race, marriage status, and *APOE4* information were retrieved from the
79 ADNIMERGE file.

80 The *APOE4* carrier status was identified from DNA extracted by Cogenics from a 3 mL aliquot of EDTA
81 blood extracted from participants during their screening visit.²⁷ Anti-diabetic medications were
82 extracted (list provided in the Supplementary File 2) using the *Anatomical Therapeutic Chemical*
83 (*ATC*) classification system coding (<https://www.who.int/tools/atc-ddd-toolkit/atc-classification>).
84 Information regarding smoking and alcohol usage was obtained from the medical history file. Finally, we
85 retained infections that only preceded the HCl measurements.

86 **2.3 Outcomes: Brain glucose hypometabolism, AD and MCI**

87 Multiple PET scanners were used to capture brain images based on a standard protocol.²⁸ Measures were
88 taken to correct for the related discrepancies.²⁹ The details regarding the PET scan and related protocols
89 can be viewed elsewhere (<https://adni.loni.usc.edu/methods/pet-analysis-method/pet-analysis/>). The

90 generated raw PET data are centrally stored at the Laboratory of Neuroimaging (LONI) at the USC Mark
91 and Mary Stevens Neuroimaging and Informatics Institute of the University of California.³⁰

92 We retrieved the processed study outcomes from the BAIPETNMRCFDG dataset
93 (<https://adni.bitbucket.io/reference/baipetnmc.html>). The main outcome of interest was the
94 hypometabolic convergence index (HCI), developed to reflect the AD-specific hypometabolism across
95 regions of the brain by computing voxel-wise z-scores from FDG-PET brain images. Higher HCI values
96 correspond to lower levels of metabolism in the brain.³¹

97 Additionally, we examined the associations for infections with statistical regions of interest (SROI)
98 corresponding to AD and Mild Cognitive Impairment (MCI). SROI associations might provide additional
99 insights into the cerebral metabolic rate for glucose (CMRgl) decline in these brain regions, helping to
100 understand the disease-specific pathology they represent.³² The Statistical Parametric Mapping (SPM)
101 software was used to generate the HCI and SROI scores.^{32,33} The work of Landau et al. provides further
102 details on the generation and development of regions of interest in the ADNI cohort.³⁴ A decline in FDG-
103 PET Region of Interest (ROI) values suggests pathological brain damage and may contribute to the
104 progression of dementia.³³

105 **2.4 Statistical Analysis**

106 R version 4.3.2 was used for the data linking and statistical analysis.³⁵ We analyzed the dataset with full
107 covariate and outcome information, without performing any imputations. The *ggplot2* package was used
108 to create variable distribution plots.³⁶ The leptokurtic HCI readings were normalized during the *RNomni*
109 package.³⁷ Multivariate linear regression models were conducted for all specified outcomes separately.
110 Age, education, and allele dosages of *APOE ε4* were analyzed as continuous variables. Infections, AD, and
111 diabetes medications were coded as a binary variable (yes or no). Marriage, smoking, and alcohol use
112 were coded as Ever or Never. We explored models with a full set and a reduced set of covariates. The

113 parsimonious model (best explanatory model) was determined using the Akaike Information Criterion
114 (AIC) in the *MuMin* package.³⁸ A two-sided p-value less than 0.05 was considered to support our
115 hypothesis.

116 A *Random Forest-based* model was used to rank the significant variables according to their contributions
117 to the best model.³⁹ The effect modification for infections with HCl by *APOE4* carrier status was assessed
118 by visualizing with the *rockchalk* package.⁴⁰ Marginal mean estimates were calculated to show the
119 interaction effects for the infections across categories of *APOE4* and sex.

120 **2.5 Ethics Approval**

121 The Institutional Review Board of Duke University Health System issued approval for this study (Protocol
122 IDs Pro00109279 and Pro00105389). All participants provided written informed consent. ADNI studies
123 follow Good Clinical Practices guidelines, the Declaration of Helsinki, and United States regulations (U.S.
124 21 CFR Part 50 and Part 56).

125 **3 Results**

126 **3.1 Participant Characteristics**

127 The final sample included information on 1,509 participants after data linking (Supplementary Figure 2).
128 As shown in Table 1, the average age among participants was 73.3 years, with an average education
129 duration of 16.0 years (IQR 14.0-18.0). Over 96% of respondents reported being ever married, and 55.8%
130 were males. There was a relatively lower representation of non-white individuals, totaling 116 (7.6%) in
131 the sample. Percentage of individuals with a history of smoking and alcohol use was 27.1% and 3.3%,
132 respectively. Of these, 215 individuals accounting for 14.2% of the total sample size, reported having
133 infections. The median interval between biomarker assessment and infections was 8.4 (IQR: 3.5 - 28.3).
134 Median HCl was 12.59, and the IQR was 8.4 - 19.3.

135 Figure 1 shows the distributions of the original HCl and rank-normalized HCl and also a scatterplot of their
136 relationship. For AD and MCI participants, the mean SROI values were 1.15 and 1.03, respectively. About
137 3% of participants with diabetes were on medication, and 18.3% had an AD diagnosis. Peptic ulcer disease
138 (PUD) (n=152), urinary tract infection (UTI) (n=146), and pneumonia (n=102) were the most frequent
139 among the selected infections. Supplementary Figure 3 shows the difference in the distribution of HCl
140 values for individuals with infections, AD, and *APOE4*. The median HCl value among individuals with
141 infections was 13.64, while it was lower (12.48) for those without infections. It was also seen that the HCl
142 had a modest positive correlation with *APOE4* (Supplementary Figure 4).

143

144 Table 1. Demographic and clinical characteristics of the study population


Variable	Mean/Median /Frequency	SD/IQR	Range
Age (Years) #	73.3	7.2	55.0-91.4
Male (%)	843 (55.8%)		
Education (Years) #	16.0	14.0-18.0	4.0-20.0
Marriage Status			
Ever	1455 (96.4%)		
Never	54 (3.5%)		
Race			
White	1393 (92.3%)		
Other	116 (7.6%)		
Smoking (Ever)	409 (27.1%)		
Alcohol (Ever)	50 (3.3%)		
Infections (Yes)	215 (14.2%)		

Time duration (Years) #[@]	8.4	3.5-28.3	0.03-86.7
HCI #	12.59	8.4-19.3	2.3-55.2
SROI AD	1.15	0.08	0.8-1.38
SROI MCI	1.03	0.10	0.7-1.35
<i>APOE4</i>[§]			
0	813 (53.8%)		
1	544 (36.0%)		
2	152 (10.0%)		
Diabetes (Yes)			
AD	277 (18.3%)		

Note. Data are presented as mean \pm standard deviation (SD) or percentage (%) for continuous and categorical variables, respectively; #Variables with skewed distributions are presented as median and IQR. [§]Frequencies in the analyzed sample. [@]Time from Infection to HCI measurements.

145

146



147

148 Figure 1. Distribution of HCI and normalized HCI with scatterplot showing their relationship

149 3.2 Association of Infections and Other Predictors with the HCI

150 Supplementary Table 1 shows the regression estimates for all the predictors in the multivariate linear
151 regression full model for HCI outcome. Marriage status, education, smoking, alcohol, and diabetes
152 medication use were not significant predictors of HCI. Table 2 presents the results of the reduced model,
153 which best describes the model variance. AD status predicted the strongest reduction in brain metabolism
154 [$\beta = 1.04$, 95% CI 0.92-1.15, $p < 0.001$], followed by age [$\beta = 0.01$, 95% CI 0.01-0.02, $p < 0.001$] and *APOE4*
155 carrier status [$\beta = 0.32$, 0.25-0.38, $p < 0.001$]. Higher variable relevance is indicated by higher values of
156 %INCMSE and INCNodepurity (Supplementary Table 2). The regression coefficient for infections was 0.15
157 [95% CI 0.02- 0.27, $p = 0.01$]. Males and white people were at higher risk of having elevated HCI values.
158 Smoking history was the only non-significant predictor retained in the reduced model. The adjusted R-
159 squared from the reduced model was 26.9%. Males had higher median HCI values.

160 In the sex-stratified analysis evaluating the effects of infections versus non-infections, males generally
161 demonstrated relatively higher HCl values (Supplementary Table 3). The difference in normalized marginal
162 means between all groups was statistically significant ($p < 0.001$). The combined effects of infections and
163 *APOE4* carrier status on HCl levels are shown in Figure 2. This was significantly greater than the effects of
164 either variable alone. Supplementary Table 4 clarifies these results. Specifically, for individuals without
165 infections and *APOE4* carrier status, the estimated marginal mean was 0.03 ($p = 0.53$). However, this
166 increased significantly to 0.18 ($p < 0.001$) for *APOE4* non-carriers in the presence of infections. Notably,
167 among *APOE4* carriers, the estimated marginal mean was substantially higher at 0.62, and this value rose
168 to 0.77 with infections ($p < 0.001$), confirming an interaction between the two factors.

169 This interaction was further demonstrated in the additional analysis (Supplementary Table 5 and Figure
170 3), indicating that carriers who experienced multiple infections exhibited greater hypometabolism. Among
171 individuals with more than one prior infection ($n = 23$), the estimate was significantly higher at 0.44
172 ($p = 0.01$) compared to those with a single infection, which was 0.11 ($p = 0.08$), revealing a dose-response
173 relationship.

174

175 Table 2. Regression estimates for predictors in the reduced multivariate linear regression model for HCl
176 outcome

Variables	Estimates	95% CI	P
AD (Yes)	1.04	0.92, 1.15	<0.001***
<i>APOE4</i>	0.32	0.25, 0.38	<0.001***
Age	0.01	0.01, 0.02	<0.001***

Infections (Yes)	0.15	0.02, 0.27	0.01*
Race (White)	0.25	0.09, 0.42	0.002**
Sex (Male)	0.17	0.09, 0.26	<0.001***
Smoking (Yes)	0.08	-0.01, 0.18	0.085

177 Note. *p<0.05; **p<0.01; ***p<0.001.

178

179

180

181

182

183

184

185

186





Figure 2. Joint effect of *APOE4* and history of infections on HCl



187

188 **Figure 3.** Brain hypometabolism by *APOE4* carrier status and frequency of infections

189

190 3.3 Association of Infections and Other Predictors with the SROI AD

191 Supplementary Table 6 provides regression estimates for all the factors investigated for SROI AD.

192 Marriage, race, smoking, and alcohol history were not significant predictors of AD-specific

193 hypometabolism. In the reduced model shown in Table 3, AD was associated with increased region-

194 specific hypometabolism (regression coefficient: -0.08, $p < 0.001$). The use of diabetes medications was

195 associated with decreased brain metabolism (-0.03, $p = 0.02$). Similar to previous regression, an increase in

196 *APOE4* alleles was a strong risk factor for hypometabolism (-0.02, $p < 0.001$). Male gender showed greater

197 hypometabolism (-0.01, $p < 0.01$). Although education was linked to a better metabolic pattern, this

198 relationship was not profound. Age-specific decreases were not as notable as those observed in HCl (-

199 0.003, $p < 0.001$). While statistically significant, the effect estimate for previous infections was lower for
200 AD (-0.01 , $p = 0.02$). These variables collectively predicted 26.8% of the variance in SROI AD.

201 Table 3. Regression estimates for predictors in the reduced multivariate linear regression model for SROI
202 AD outcome

Variables	Estimates	95% CI	P
AD (Yes)	-0.08	-0.09, -0.07	<0.001***
<i>APOE4</i>	-0.02	-0.03, -0.02	<0.001***
Age	-0.003	-0.003, -0.002	<0.001***
Diabetes Medication	-0.03	-0.05, -0.004	0.02*
Education	0.001	0.00, 0.002	0.04*
Infections (Yes)	-0.01	-0.02, -0.001	0.02*
Sex (Male)	-0.01	-0.02, -0.003	0.00**
Smoking (Yes)	-0.01	-0.02, 0.001	0.11

203 Note. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

204

205 3.4 Association of Infections and Other Predictors with the SROI MCI

206 The results of the SROI MCI regression (full model) is presented in the Supplementary Table 7. Generally,
207 the estimates were closer to the SROI AD than HCI. Among the variables that best explained the model
208 (Table 4), AD, *APOE4*, and diabetes medications had the largest effect estimates.
209 Sex and use of diabetic medications had a marginally greater impact on the MCI region than on the AD
210 region. However, race and education were not identified as significant predictors. Infections were

211 associated with a -0.01 reduction in regional metabolism ($p=0.04$). The percentage of variation explained
212 by the model for the SROI MCI was also the highest (28.8%) of the three investigated outcomes.

213 Table 4. Regression estimates for predictors in the reduced multivariate linear regression model for SROI
214 MCI outcome

Variables	Estimates	95% CI	P
AD (Yes)	-0.09	-0.10, -0.08	<0.001***
<i>APOE4</i>	-0.02	-0.03, -0.02	<0.001***
Age	-0.004	-0.01, -0.003	<0.001***
Diabetes Medication (Yes)	-0.04	-0.06, -0.01	0.01**
Infections (Yes)	-0.01	-0.03, -0.0005	0.04*
Sex (Male)	-0.02	-0.03, -0.01	<0.001***
Smoking (Yes)	-0.01	-0.02, 0.003	0.15

215 Note. * $p<0.05$; ** $p<0.01$; *** $p<0.001$.

216

217 4 Discussion

218 Results of our study suggest that infections and *APOE4* can jointly significantly affect brain glucose
219 metabolism, specifically promote hypometabolism, as measured by the increased values of HCl. A history
220 of infections in this ADNI sample corresponds to a greater hypometabolism, specifically a 0.15 unit
221 increase in rank normalized HCl. However, this estimate rises to 0.44 in the presence of multiple
222 infections. Model inclusion of established confounders such as age, sex, race, and education did not
223 diminish these findings. We also adjusted for AD status, which was more prevalent in the group with no

224 infections and associated with reduced brain metabolism. Adjusting for AD status and *APOE4* was
225 necessary to reveal the genuine association of previous infections. Additionally, previous infections were
226 significantly associated with regional brain metabolism specific to AD and MCI in our data.

227 Our findings agree with previous research suggesting that infections may negatively impact brain
228 metabolism.^{16,41–43} Infectious diseases, including those addressed in this study, have been previously
229 linked to AD in other data.^{22,44–46} Our recent paper that used Health and Retirement Study (HRS) data
230 reported associations between AD and various infectious (viral, bacterial, fungal), suggesting that
231 compromised immunity may play a role in AD etiology.²⁰ The connection between infections and brain
232 hypometabolism may also involve pathological immune responses. Some research provides indirect
233 support to this idea by linking brain hypometabolism to microglia activation.^{47–49}

234 Determining the onset time of infection is a major challenge in AD research. Furthermore, the causal
235 inferences are obscured by the fact that individuals with AD often grapple with a variety of infections due
236 to declining immunity, leading to elevated antimicrobial markers.¹⁶ Pathogens have a high affinity to the
237 central nervous system and brain tissues and could affect cognition.⁵⁰ Given that brain hypometabolism
238 is an early sign of AD, our findings suggest that infections could potentially trigger this process.⁵¹ However,
239 the progression of hypometabolism may also depend upon the combination of other risk factors.⁵²

240 Infections can affect the brain through multiple pathways, both directly and indirectly, particularly when
241 the blood-brain barrier is breached.^{53,54} Infections propagated through the respiratory route can also
242 reach the brain relatively easily.^{50,55} However, upon reaching the brain, different infectious agents employ
243 their preferred mechanisms, such as latent activation and the initiation of inflammation, as seen in the
244 case of the Herpes virus.⁵⁶ Pathogen invasion into the brain leads to chronic inflammation, which can
245 compromise the blood-brain barrier.⁴² There are distinct differences in inflammatory pathways noted
246 across specific pathogens.^{19,57} Age-related changes could exacerbate these pathological processes even
247 further.⁵⁸ Strom and colleagues have also demonstrated that brain hypometabolism correlates with tau

248 pathology and neurodegeneration in crucial dementia-specific regions within the ADNI dataset.⁵⁹ These
249 mechanisms could potentially explain a significant portion of the biological processes leading up to
250 hypometabolism.

251 Studies on the relationship between *APOE4* and brain metabolism have produced contrasting findings.^{59–}
252 ⁶³ In their recently published work, Fortea and colleagues found that simply being homozygous for *APOE4*
253 is sufficient, in most cases, to guarantee an AD diagnosis.⁶⁴ In our analysis, the increase in *APOE4* allele
254 was associated with all three outcomes and showed compounding effects with infections and their
255 burden. Even in patients with a single *APOE4* variant, which is usually not considered a significant increase
256 in risk compared to homozygous carriers, the presence of infections increases the risk of hypometabolism
257 to nearly the same level as in homozygous *APOE4* carriers. One possibility is that the observed effect is
258 due to accelerated neuroinflammation arising from the presence of both risk factors.⁶⁵ Risk factors for AD
259 tend to cluster in individuals with *APOE* risk alleles, including a reduction in brain metabolism.⁶⁶ Amyloid-
260 beta and Tau deposition are higher in *APOE4* carriers.⁶⁷ *APOE4* can also accelerate brain degeneration
261 through non-overlapping pathways independent of amyloid deposition and Tau pathology.^{68–70} *APOE4*
262 alleles both promote and resist infections, depending on the type of infection.⁷¹ Researchers suggest that
263 *APOE4* polymorphisms result in increased lipid production⁷² and blood-brain barrier loss⁷³, which could
264 facilitate a conducive environment for pathogens.⁷⁴ Supporting evidence from the Northern Manhattan
265 Study showed that the effect-modifying relationship between *APOE4* and infectious burden was
266 correlated with decreased cognition.⁷⁵ The influence of *APOE4* on AD remains incompletely understood,
267 although it is known to engage in intricate interactions with other risk factors for AD, such as age.^{76,77}
268 However, in stark contrast to these findings, a study reported that the effects of *APOE4* on cognition are
269 AD-specific. It singles out the cause of cognitive decline as the interaction between *APOE4* and amyloid
270 beta in the hippocampus.⁷⁸

271 Our study revealed that diabetes medication was the third-biggest risk factor for AD and MCI-specific
272 brain metabolism, but not for the HCl measure. Previous studies indeed demonstrated that diabetes
273 increases the risk for MCI and AD.^{79,80} Individuals with diabetes and AD often share common biological
274 pathways.⁸¹ Most prominent among these are low-grade chronic inflammation and insulin resistance.⁸²

275 Sex differences in mechanisms related to AD warrant in-depth study. Usually, females are susceptible to
276 AD and early brain hypometabolism compared to males.^{83,84} On exposure to prior infections, women are
277 also, particularly at higher risk for reduced hippocampal volume.¹⁹ Males overall had a higher HCl value
278 than females in our sample. It is important to note that males with infections had a slightly higher mean
279 age. But this alone cannot explain the gender difference. Importantly, there was no difference in the
280 increase in marginal means due to infections for both sexes. An earlier study reported that brain
281 hypometabolism increased in men after 70 years of age, while this was not seen in females in a normal
282 brain.⁸⁵ However, the applicability of this finding in the AD context needs confirmation. Some participant
283 characteristics in ADNI may differ from the general population due to voluntary recruitment. Variations
284 in the distribution of AD risk factors among genders might also contribute to this finding.^{86,87}

285 Given that AD is not curable, prevention stands as the most viable option at present. Vaccinations may
286 potentially alleviate AD risk. Influenza vaccines, in particular, are among the candidates demonstrating
287 this preventive potential.^{4,79} However, personal genetics could play a role in determining the efficacy and
288 effectiveness of vaccinations. Recent research has revealed that individuals carrying a polymorphism in
289 the *NECTIN2* gene exhibit a decreased susceptibility to AD when compared to non-carriers, when receiving
290 vaccinations for pneumonia and flu.²²

291 The availability of medical history information and longitudinally standardized FDG PET measurements
292 were important strengths of our study. We were also able to demonstrate the temporality of association,
293 which was rarely described in earlier human studies.⁸⁸ There were a couple of study limitations. Of these,

294 the most important is that the medical history is questionnaire-based, suggesting that recall bias may exist
295 and lead to an incorrect exposure classification. Currently, the representation of high-risk groups, such as
296 Afro-American and Hispanic individuals, is limited in the ADNI database, which has constrained the
297 evaluation of the effect modification role of race in relation to infections and brain hypometabolism.⁸⁹ In
298 this work, we did not specifically explore the heterogeneity in infections and the brain metabolism
299 relationship. However, previous AD studies indicate that there could be subgroups that may be
300 differentially vulnerable.⁹⁰⁻⁹² There may also be a cohort effect, wherein the frequency of infections
301 observed within this group may not accurately fit the current disease landscape. We recommend
302 validating the findings in large cohorts with robust information on prior infections.

303

304 **5 Conclusion**

305 This study found that infections and *APOE4* jointly promote brain glucose hypometabolism in older ADNI
306 participants. In individuals with history of infections who were also carriers of one *APOE4* allele, the degree
307 of brain glucose hypometabolism was nearly that seen in *APOE4* homozygotes without prior infections.
308 We conclude that prior infections may contribute to AD pathology in synergy with *APOE4*, thus playing a
309 part in the “multi-hit” mechanism of AD development.

310

311 **Data Availability**

312 The data used in this manuscript were obtained from the publicly available ADNI database
313 (adni.loni.usc.edu). The ADNI database contains anonymized patient information, making it a secure data
314 repository.

315 **Funding**

316 This research was supported by the National Institutes of Health's National Institute on Aging (NIA/NIH)
317 grants R01AG076019 and R01AG062623. This content is solely the responsibility of the authors and does
318 not necessarily represent the official views of the NIA/NIH.

319

320 **Abbreviations**

AD	Alzheimer's disease
AIC	Akaike Information Criterion
<i>APOE</i>	Apolipoprotein E
A β	Amyloid β
FDG	18F-fluorodeoxyglucose
GxE	Gene-environment interaction
GWAS	Genome-wide association studies
HSV	Herpes Simplex Virus
%INCMSE	Percent Increase in Mean Squared error
IQR	Interquartile Range
PET	Positron Emission Tomography
pTau	Phosphorylated Tau
SD	Standard Deviation
SNP	Single Nucleotide Polymorphism
SROI	Statistical Region of Interest
<i>NECTIN2</i>	Nectin Cell Adhesion Molecule 2 (gene)
PUD	Peptic Ulcer Disease
UTI	Urinary Tract Infection

321 **References**

- 322 1. Tupler L, Yashkin A, Hoque M, Yashin A, Akushevich I, Stallard E. differences in cognitive
323 decline due to Alzheimer’s disease, neurodegenerative disorders, and trauma. *Innov Aging.*
324 2023;7(Suppl 1):852.
- 325
- 326 2. 2023 Alzheimer’s disease facts and figures. *Alzheimer’s Dement.* 2023;19:1598–695.
- 327
- 328 3. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical
329 Alzheimer’s disease: Definition, natural history, and diagnostic criteria. *Alzheimers Dement.*
330 2016;12(3):323.
- 331
- 332 4. Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, et al. Identification
333 of preclinical Alzheimer’s disease by a profile of pathogenic proteins in neurally derived
334 blood exosomes: A case-control study. *Alzheimer’s & Dementia.* 2015;11(6):600-607.
- 335
- 336 5. Blázquez E, Hurtado-Carneiro V, LeBaut-Ayuso Y, Velázquez E, García-García L, Gómez-
337 Oliver F, et al. Significance of Brain Glucose Hypometabolism, Altered Insulin Signal
338 Transduction, and Insulin Resistance in Several Neurological Diseases. *Front Endocrinol*
339 (Lausanne). 2022;13(873301).

340

- 341 6. Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for
342 diagnosis and staging of Alzheimer’s disease. *Nat Med*. 2024;30(8):2121–4.
343
- 344 7. Atamna H, Frey WH. Mechanisms of mitochondrial dysfunction and energy deficiency in
345 Alzheimer’s disease. *Mitochondrion*. 2007;7(5):297–310.
346
- 347 8. Herholz K. PET studies in dementia. *Ann Nucl Med*. 2003;17(2):79–89.
348
- 349 9. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s
350 disease. FDG-PET studies in MCI and AD. *Eur J Nucl Med Mol Imaging*. 2005;32(4):486–510.
351
- 352 10. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al.
353 Alzheimer’s disease. *Lancet*. 2021;397(10284):1590.
354
- 355 11. Tanzi RE. The Genetics of Alzheimer Disease. *Cold Spring Harb Perspect Med* [Internet].
356 2012;2(10):a006296.
357
- 358 12. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia
359 prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*.
360 2020;396(10248):446.

361

362 13. De La Torre JC. Alzheimer's disease is incurable but preventable. *J Alzheimers Dis.*
363 2010;20(3):70.

364

365 14. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. *Nat Rev Neurol.*
366 2010;6:681–94.

367

368 15. Mcmurry HS, Mendenhall E, Rajendrakumar A, Nambiar L, Satyanarayana S, Shivashankar
369 R. Coprevalence of type 2 diabetes mellitus and tuberculosis in low - income and middle -
370 income countries: A systematic review. *Diabetes Metab Res Rev.* 2019;35(2018).

371

372 16. Viasova D, Nemergut M, Liskova B, Damborsky J. Multi-pathogen infections and
373 Alzheimer's disease. *Microb Cell Fact.* 2021;20(25).

374

375 17. Rippee-Brooks MD, Wu W, Dong J, Pappolla M, Fang X, Bao X. Viral Infections, Are They a
376 Trigger and Risk Factor of Alzheimer's Disease? *Pathogens.* 2024;13(3):240.

377

378 18. Paranjpe MD, Belonwu S, Wang JK, Oskotsky T, Gupta A, Taubes A, et al. Sex-Specific Cross
379 Tissue Meta-Analysis Identifies Immune Dysregulation in Women With Alzheimer's Disease.
380 *Front Aging Neurosci.* 2021;13(735611).

381

- 382 19. Popov VA, Ukraintseva S, Duan H, Arbeev KG, Yashin AI. Prior infections are associated with
383 smaller hippocampal volume in older women. *Front Dement.* 2024;3(2024).
- 384
- 385 20. Ukraintseva S, Yashkin AP, Akushevich I, Arbeev K, Duan H, Gorbunova G, et al. Associations
386 of infections and vaccines with Alzheimer’s disease point to a role of compromised
387 immunity rather than specific pathogen in AD. *Exp Gerontol.* 2024;190.
- 388
- 389 21. Rajendrakumar L, Ukraintseva S, Arbeev KG, Bagley O, Yashin AI. The association between
390 rs6859 in NECTIN2 gene and Alzheimer’s disease is partly mediated by pTau. *Front Aging*
391 *Neurosc.* 2024;16.
- 392
- 393 22. Ukraintseva S, Duan M, Simanek AM, Holmes R, Bagley O, Rajendrakumar AL, et al.
394 Vaccination Against Pneumonia May Provide Genotype-Specific Protection Against
395 Alzheimer’s Disease. *J Alzheimers Dis.* 2023;96(2):499–505.
- 396
- 397 23. Hosp JA, Dressing A, Blazhenets G, Bormann T, Rau A, Schwabenland M, et al. Cognitive
398 impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19.
399 *Brain.* 2021;144(4):1263–76.

400

- 401 24. Weber CJ, Carrillo MC, Jagust W, Jack CR, Shaw LM, Trojanowski JQ, et al. The Worldwide
402 Alzheimer’s Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives.
403 Alzheimers Dement (N Y). 2021;7(1):e12226.
404
- 405 25. Ashford MT, Raman R, Miller G, Donohue MC, Okonkwo OC, Mindt MR, et al. Screening and
406 enrollment of underrepresented ethnocultural and educational populations in the
407 Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimer’s Dement. 2022;1–11.
408
- 409 26. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer’s
410 Disease Neuroimaging Initiative (ADNI) Clinical characterization. Neurology. 2010;74:201–
411 9.
412
- 413 27. Sudre CH, Cardoso MJ, Frost C, Barnes J, Barkhof F, Fox N, et al. APOE ε4 status is associated
414 with white matter hyperintensities volume accumulation rate independent of AD diagnosis.
415 Neurobiol Aging. 2017;53:67–75.
416
- 417 28. Langbaum JBS, Chen K, Lee W, Reschke C, Bandy D, Fleisher AS, et al. Categorical and
418 correlational analyses of baseline fluorodeoxyglucose positron emission tomography
419 images from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Neuroimage.
420 2009;45(4):1116.
421

- 422 29. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer's Disease
423 Neuroimaging Initiative positron emission tomography core. *Alzheimer's & Dementia*.
424 2010;6(3):221–9.
- 425
- 426 30. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, et al. The Alzheimer's
427 Disease Neuroimaging Initiative. *Neuroimaging Clin N Am*. 2005;15(4):869-77.
- 428
- 429 31. Chen K, Ayutyanont N, Langbaum JBS, Fleisher AS, Reschke C, Lee W, et al. Characterizing
430 Alzheimer's disease using a hypometabolic convergence index. *Neuroimage*. 2011;56:52–
431 60.
- 432
- 433 32. Chen K, Langbaum JBS, Fleisher AS, Ayutyanont N, Reschke C, Lee W, et al. Twelve-month
434 metabolic declines in probable Alzheimer's disease and amnesic mild cognitive impairment
435 assessed using an empirically pre-defined statistical region-of-interest: Findings from the
436 Alzheimer's Disease Neuroimaging Initiative. *Neuroimage*. 2010;51(2):654–64.
- 437
- 438 33. Ewers M, Brendel M, Rizk-Jackson A, Rominger A, Bartenstein P, Schuff N, et al. Reduced
439 FDG-PET brain metabolism and executive function predict clinical progression in elderly
440 healthy subjects. *Neuroimage Clin*. 2014;4:45–52.
- 441

- 442 34. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations
443 between cognitive, functional, and FDG-PET measures of decline in AD and MCI.
444 Neurobiol Aging. 2011:1207–18.
- 445
- 446 35. R Core Team. R: A language and environment for statistical computing. R Foundation for
447 Statistical Computing, Vienna, Austria [Internet]. 2021 [cited 2023 May 15]. Available from:
448 <https://www.R-project.org/>
- 449
- 450 36. Wickham H. ggplot2: Elegant Graphics for Data Analysis Using the Grammar of Graphics
451 [Internet]. Springer-Verlag New York; 2016. Available from: <https://ggplot2.tidyverse.org>.
- 452
- 453 37. McCaw Z. RNOmni: Rank Normal Transformation Omnibus Test [Internet]. 2020. Available
454 from: <https://CRAN.R-project.org/package=RNOmni>
- 455
- 456 38. Bartoń K. MuMIn: Multi-model inference [Internet]. Vol. 1, R package version 1.10.0. 2013.
457 Available from: <https://cran.r-project.org/web/packages/MuMIn/MuMIn.pdf>
- 458
- 459 39. Liaw A, Wiener M. Classification and Regression by randomForest. R News [Internet]. 2002
460 [cited 2024 May 2];2(3):18–22. Available from: <http://www.stat.berkeley.edu/>
- 461

- 462 40. Johnson PE. Using rockchalk for Regression Analysis * [Internet]. 2017 [cited 2024 Apr 30].
463 Available from: <http://cran.nexr.com/web/packages/rockchalk/vignettes/rockchalk.pdf>
464
- 465 41. Ashraf GM, Tarasov V V, Makhmutova A, Chubarev VN, Avila-Rodriguez M, Bachurin SO, et
466 al. The Possibility of an Infectious Etiology of Alzheimer Disease. *Mol Neurobiol.*
467 2019;56:4479–91.
468
- 469 42. Shinjyo N, Kita K. Infection and Immunometabolism in the Central Nervous System: A
470 Possible Mechanistic Link Between Metabolic Imbalance and Dementia. *Front Cell*
471 *Neurosci.* 2021;15(765217).
472
- 473 43. Butler L, Walker KA. The Role of Chronic Infection in Alzheimer’s Disease: Instigators, Co-
474 conspirators, or Bystanders? *Curr Clin Micro Rpt.* 2021;8:199–212.
475
- 476 44. Cairns DM, Itzhaki RF, Kaplan DL. Potential Involvement of Varicella Zoster Virus in
477 Alzheimer’s Disease via Reactivation of Quiescent Herpes Simplex Virus Type 1. *J Alzheimers*
478 *Dis.* 2022;88(3):1189–200.
479
- 480 45. Bukhbinder AS, Ling Y, Hasan O, Jiang X, Kim Y, Phelps KN, et al. Risk of Alzheimer’s Disease
481 Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity Score
482 Matching. *J Alzheimers Dis.* 2022;88(3):1061–74.

483

484 46. Noori M, Mahboobi R, Nabavi-Rad A, Jamshidizadeh S, Fakharian F, Yadegar A, et al.
485 Helicobacter pylori infection contributes to the expression of Alzheimer's disease-
486 associated risk factors and neuroinflammation. Heliyon. 2023;9(9):e19607.

487

488 47. Tondo G, Boccalini C, Caminiti SP, Presotto L, Filippi M, Magnani G, et al. Brain Metabolism
489 and Microglia Activation in Mild Cognitive Impairment: A Combined [18F]FDG and [11C]-
490 (R)-PK11195 PET Study. J Alzheimers Dis. 2021;80(1):433–45.

491

492 48. Kadamani KL, Logan SM, Pamerter ME. Does hypometabolism constrain innate immune
493 defense? Acta Physiol. 2024;240:e14091.

494

495 49. Aldana BI. Microglia-Specific Metabolic Changes in Neurodegeneration. J Mol Biol.
496 2019;431(9):1830–42.

497

498 50. Guedj E, Million M, Dudouet P, Tissot-Dupont H, Bregeon F, Cammilleri S, et al. 18F-FDG
499 brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed
500 disorders? Eur J Nucl Med Mol Imaging. 2021;48(2):592–5.

501

502 51. Zilberter Y, Zilberter M. The vicious circle of hypometabolism in neurodegenerative
503 diseases: Ways and mechanisms of metabolic correction. J Neurosci Res. 2017;95:2217–35.

504

505 52. Yang Z, Cummings JL, Kinney JW, Cordes D. Accelerated hypometabolism with disease
506 progression associated with faster cognitive decline among amyloid positive patients. *Front*
507 *Neurosci.* 2023;17.

508

509 53. Sweeney MD, Sagare AP, Zlokovic B V. Blood-brain barrier breakdown in Alzheimer disease
510 and other neurodegenerative disorders. *Nat Rev Neurol.* 2018;14(3):133–50.

511

512 54. Sochocka M, Zwolińska K, Leszek J. The Infectious Etiology of Alzheimer’s Disease. *Curr*
513 *Neuropharmacol.* 2017;15(7):996–1009.

514

515 55. Wan D, Du T, Hong W, Chen L, Que H, Lu S, et al. Neurological complications and infection
516 mechanism of SARS-COV-2. *Signal Transduct Target Ther.* 2021;6(406).

517

518 56. Lövheim H, Gilthorpe J, Adolfsson R, Nilsson LG, Elgh F. Reactivated herpes simplex infection
519 increases the risk of Alzheimer’s disease. *Alzheimer’s & Dementia.* 2015;11(6):593–9.

520

521 57. Chhatbar C, Prinz M. The roles of microglia in viral encephalitis: from sensome to
522 therapeutic targeting. *Cell Mol Immunol.* 2021;18:250–8.

523

- 524 58. Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, et al. Blood-brain
525 barrier breakdown in the aging human hippocampus. *Neuron*. 2015;85(2):296–302.
- 526
- 527 59. Strom A, Iaccarino L, Edwards L, Lesman-Segev OH, Soleimani-Meigooni DN, Pham J, et al.
528 Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic
529 Alzheimer’s disease. *Brain*. 2022;145(2):713–28.
- 530
- 531 60. Corder EH, Jelic V, Bosun H, Lannfelt L, Valind S, Winblad B, et al. No Difference in Cerebral
532 Glucose Metabolism in Patients With Alzheimer Disease and Differing Apolipoprotein E
533 Genotypes. *Arch Neurol*. 1997;54(3):273–7.
- 534
- 535 61. Rabinovici GD, Furst AJ, Alkalay A, Racine CA, O’Neil JP, Janabi M, et al. Increased metabolic
536 vulnerability in early-onset Alzheimer’s disease is not related to amyloid burden. *Brain*.
537 2010;133(2):512–28.
- 538
- 539 62. Lehmann M, Ghosh PM, Madison C, Karydas A, Coppola G, O’Neil JP, et al. Greater medial
540 temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD
541 patients. *J Neurol Neurosurg Psychiatry*. 2014;85(3):266–73.
- 542

- 543 63. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical Evidence of
544 Alzheimer’s Disease in Persons Homozygous for the ϵ 4 Allele for Apolipoprotein E. *N Engl J*
545 *Med.* 1996;334:752–8.
- 546
- 547 64. Fortea J, Pegueroles J, Alcolea D, Belbin O, Dols-Icardo O, Vaqué-Alcázar L, et al. APOE4
548 homozygosity represents a distinct genetic form of Alzheimer’s disease. *Nat Med.*
549 2024;30:1284–91.
- 550
- 551 65. Finch CE, Morgan TE. Systemic Inflammation, Infection, ApoE Alleles, and Alzheimer
552 Disease: A Position Paper. *Curr Alzheimer Res.* 2007 ;4(5):185–9.
- 553
- 554 66. Duong MT, Nasrallah IM, Wolk DA, Chang CCY, Chang TY. Cholesterol, Atherosclerosis, and
555 APOE in Vascular Contributions to Cognitive Impairment and Dementia (VCID): Potential
556 Mechanisms and Therapy. *Front Aging Neurosci.* 2021;13(647990).
- 557
- 558 67. Fernández-Calle R, Konings SC, Frontiñán-Rubio J, García-Revilla J, Camprubí-Ferrer L,
559 Svensson M, et al. APOE in the bullseye of neurodegenerative diseases: impact of the APOE
560 genotype in Alzheimer’s disease pathology and brain diseases. *Mol Neurodegeneration.*
561 2022;17(62).
- 562

- 563 68. Farmer BC, Williams HC, Devanney NA, Piron MA, Nation GK, Carter DJ, et al. APOE4 lowers
564 energy expenditure in females and impairs glucose oxidation by increasing flux through
565 aerobic glycolysis. *Mol Neurodegener.* 2021;16(1):62.
- 566
- 567 69. Calderón-Garcidueñas L, Hernández-Luna J, Aiello-Mora M, Brito-Aguilar R, Evelson PA,
568 Villarreal-Ríos R, et al. APOE Peripheral and Brain Impact: APOE4 Carriers Accelerate Their
569 Alzheimer Continuum and Have a High Risk of Suicide in PM2.5 Polluted Cities.
570 *Biomolecules.* 2023;13(6):927.
- 571
- 572 70. Sohn HY, Kim SI, Park JY, Park SH, Koh YH, Kim J, et al. ApoE4 attenuates autophagy via
573 FoxO3a repression in the brain. *Sci Rep.* 2021;11:17604.
- 574
- 575 71. Chen F, Ke Q, Wei W, Cui L, Wang Y. Apolipoprotein E and viral infection: Risks and
576 Mechanisms. *Mol Ther Nucleic Acids.* 2023;33:529–42.
- 577
- 578 72. Garcia AR, Finch C, Gatz M, Kraft T, Rodriguez DE, Cummings D, et al. Apoe4 is associated
579 with elevated blood lipids and lower levels of innate immune biomarkers in a tropical
580 amerindian subsistence population. *Elife.* 2021;10:e68231.
- 581
- 582 73. Raulin AC, Doss S V., Trottier ZA, Ikezu TC, Bu G, Liu CC. ApoE in Alzheimer’s disease:
583 pathophysiology and therapeutic strategies. *Mol Neurodegeneration.* 2022;17(72).

584

585 74. Urosevic N, Martins RN. Infection and Alzheimer’s disease: the APOE epsilon4 connection
586 and lipid metabolism. *J Alzheimers Dis.* 2008;13(4):35.

587

588 75. Zhao C, Strobino K, Moon YP, Cheung YK, Sacco RL, Stern Y, et al. APOE ε4 modifies the
589 relationship between infectious burden and poor cognition. *Neurol Genet.* 2020;6(4): e462.

590

591 76. Mosconi L, Herholz K, Prohovnik I, Nacmias B, Cristofaro MTR De, Fayyaz M, et al. Metabolic
592 interaction between ApoE genotype and onset age in Alzheimer’s disease: implications for
593 brain reserve. *Jour.* 2005;76:15–23.

594

595 77. Khalifa KN. Effect of APOE e4 allele on age-related brain FDG-PET uptake in older individuals
596 at risk of dementia. *Alzheimer’s Dement.* 2023;19:e067424.

597

598 78. Fernández A, Vaquero L, Bajo R, Zuluaga P, Weiner MW, Saykin AJ, et al. Apolipoprotein E
599 ε4–related effects on cognition are limited to the Alzheimer’s disease spectrum.
600 *Geroscience.* 2022;44:195–209.

601

602 79. Li W, Risacher SL, Huang E, Saykin AJ. Type 2 diabetes mellitus is associated with brain
603 atrophy and hypometabolism in the ADNI cohort. *Neurology.* 2016;87(6):595–600.

604

- 605 80. Raut S, Bhalerao A, Powers M, Gonzalez M, Mancuso S, Cucullo L. Hypometabolism,
606 Alzheimer’s Disease, and Possible Therapeutic Targets: An Overview. *Cells*.
607 2023;12(16):2019.
- 608
- 609 81. De La Monte SM, Wands JR. Alzheimer’s Disease Is Type 3 Diabetes-Evidence Reviewed. *J*
610 *Diabetes Sci Technol*. 2008;2(6):1101–13.
- 611
- 612 82. Jayaraj RL, Azimullah S, Beiram R. Diabetes as a risk factor for Alzheimer’s disease in the
613 Middle East and its shared pathological mediators. *Saudi J Biol Sci*. 2020;27(2):736–50.
- 614
- 615 83. Nebel RA, Aggarwal NT, Barnes LL, Gallagher A, Goldstein JM, Kantarci K, et al.
616 Understanding the impact of sex and gender in Alzheimer’s disease: A call to action.
617 *Alzheimer’s and Dementia*. 2018;14(9):1171–83.
- 618
- 619 84. Zhao L, Mao Z, Woody SK, Brinton RD. Sex differences in metabolic aging of the brain:
620 insights into female susceptibility to Alzheimer’s disease. *Neurobiol Aging*. 2016;42:69–79.
- 621
- 622 85. Feng B, Cao J, Yu YP, Yang HY, Jiang YHY, Liu Y, et al. Gender-Related Differences in Regional
623 Cerebral Glucose Metabolism in Normal Aging Brain. *Front Aging Neurosci*. 2022;14.
- 624

646

647 92. Sun N, Mormino EC, Chen J, Sabuncu MR, Yeo BTT. Multi-modal latent factor exploration of
648 atrophy, cognitive and tau heterogeneity in Alzheimer's disease. Neuroimage.
649 2019;201(116043).

650

651 **Acknowledgements**

652 Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative
653 (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award
654 number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of
655 Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie,
656 Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen;
657 Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and
658 Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio;
659 GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson &
660 Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale
661 Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation;
662 Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The
663 Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private
664 sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).
665 The grantee organization is the Northern California Institute for Research and Education, and the study is
666 coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California.
667 ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

668 **Consent for publication**

669 Not applicable

670

671 **Funding**

672 This research was supported by the National Institute on Aging of the National Institutes of Health under
673 Award Numbers R01AG076019, R01AG070487. The content is solely the responsibility of the authors and
674 does not necessarily represent the official views of the National Institutes of Health.

675

676 **Author Information**

677 **Authors and Affiliations**

678 ¹*Biodemography of Aging Research Unit, Social Science Research Institute, Duke University, Durham, NC,*
679 *27708-0408, USA.*

680

681 **Contributions**

682 S.U., K.G.A., A.I.Y., and A.L.R. were involved in the hypothesis generation, study design, and study
683 supervision, and they critically revised the manuscript. A.L.R. and O.B. were responsible for data cleaning.
684 A.L.R. contributed to the analysis, interpretation of the data, and manuscript writing. All authors read and
685 approved the submitted version of the manuscript.

686

687 **Corresponding Author Information**

688 ^{\$\$}Correspondence to ALR and SU, Email address: alr75@duke.edu, Svetlana.Ukrainitseva@duke.edu

689

690 **Competing Interests**

691 The authors declare no competing interests.

692

693 **Additional Information**

694 Supplementary Material 1

695 Supplementary Material 2

696

697

698

699